Professor of Clinical Medicine; Director UCLA GI Oncology Program
Oncology
Dr. Joel R. Hecht, MD
|
|
Give Review
Joel Hecht practices Oncology. He researched medicine at Eastern Virginia Medical School. He received 2 awards: "Whos Who in Medicine and Healthcare" and "Super Doctor". Joel Hecht is a published physician. He published 52 publications, including: 'Gastrointestinal toxicity or irinotecan.' He accepts Medicare.
Publications
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroe...
- Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
- A Single Institution Experience in Compliance with Universal Screening for Lynch Syndrome in ColoRectal Cancer.
- Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory Anal...
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patien...
- A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic coloRectal cancer.
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon Cancer (AVANT): a phase 3 randomised controlled trial.
- The molecular evolution of acquired resistance to targeted EGFR blockade in coloRectal cancers.
- EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic Cancer: a phas...
- Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenoCarcinoma of the oesophagus and gastro-oesophageal junction.
- Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metas...
- Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor...
- Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refrac...
- A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with coloRectal cancer receiving pegfilgras...
- Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic coloRectal cancer.
- Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric Cancer cells and is synergistic with trastuzumab in vitro and in vivo.
- Targeted lymph node evaluation in coloRectal cancer: a decade of progress!
- A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic coloRectal cancer.
- Association of K-ras mutational status and clinical outcomes in patients with metastatic coloRectal cancer receiving panitumumab alone.
- Current and emerging therapies for metastatic coloRectal cancer: applying research findings to clinical practice.
- Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based?
- Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastroIntestinal stromal tumors expre...
- A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
- Panitumumab monotherapy in patients with previously treated metastatic coloRectal cancer.
- Panitumumab in coloRectal cancer.
- Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic coloRectal cancer.
- Successful gastrointestinal Cancer drug development.
- Panitumumab in colon Cancer: a review and summary of ongoing trials.
- An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced Gastric or gastroe...
- A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastati...
- Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic coloRectal cancer: results of a randomized phase II trial.
- Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent coloRectal cancer.
- Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic Cancer.
- Improved imaging and the clinician: the role of positron emission tomography in the management of coloRectal cancer.
- Irinotecan and paclitaxel in metastatic adenoCarcinoma of the esophagus and gastric cardia.
- Phase II trial of intravenous CI-1042 in patients with metastatic coloRectal cancer.
- Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic coloRectal cancer.
- A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic Carcinoma.
- Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic Cancer.
- Phase II trial of irinotecan in combination with amifostine in patients with advanced coloRectal carcinoma.
- Adjuvant therapy for gastric Cancer: a reality at last.
- Metastasis in coloRectal cancer: what makes the tumor aggressive?
- CT colonography: value of scanning in both the supine and prone positions.
- Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and Carcinomatous lesions of the pancreas: evidence for multistep c...
- GastroIntestinal toxicity or irinotecan.
- Gastrin-releasing peptide-induced expression of prostaglandin synthase-2 in Swiss 3T3 cells.
- Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk Breast carcinoma.
- Dietary fat and colon Cancer.
- Polymerase chain reaction-based K-ras mutation detection of pancreatic adenoCarcinoma in routine cytology smears.
- Clostridium difficile colitis secondary to intravenous vancomycin.
- Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic Cancer: a phase III trial of the National Cancer Institute of Canada Cl...
Schools
E Va Med Sch Of M C Of Hampton Rds
Northwestern University
University Of California Los Angeles
University of Chicago
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
Conditions Treated
- Abdominal Pain
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Gastroenterology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Select PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
Awards
- Whos Who in Medicine and Healthcare
- Super Doctor
Education
-
UCLA Medical Center -
McGaw Medical Center of Northwestern University -
Eastern Virginia Medical School
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1790703742 | |
| NPPES Provider LastName | HECHT | |
| NPPES Provider FirstName | JOEL | |
| NPPES Provider ZIPCode | 90095 | |
| NPPES Provider State | CA | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 178.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1790703742 |
| Last Name Of The Provider | HECHT |
| First Name Of The Provider | JOEL |
| View All |
Similar Doctors
|
Dr. David P. Yamini, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Tamara D. Trebilcock, ND
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rena D. Callahan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Omid Hamid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel J. Cole, MD |
|
|
Dr. Marilou Terpenning, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sara A. Hurvitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew E. Hendifar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lawrence Piro, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jerold Federman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan W. Simons, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marc H. Harwitt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saeed W. Sadeghi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin J. Coyne, MD |
|
|
Dr. Robert I. Lehrer, MD
This Doctor is OpenDoctor Recommended.
|